EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities

Tanzida Zubair, Debasish Bandyopadhyay iD

International Journal of Molecular Sciences · 31.01.2023 · 24 (3) · 2651

DOI: 10.3390/ijms24032651 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 31.01.2023. Verfasst von Tanzida Zubair und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 247-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptors (EGFRs) are a class of receptor tyrosine kinase that are also called ErbB1 and HER1. EGFR tyrosine kinase activity inhibition is considered a promising therapeutic strategy for the treatment of cancer. Many small-molecule inhibitors of EGFR tyrosine kinase (EGFR-TK), from medicinally privileged molecules to commercial drugs, have been overviewed. Particular attention has been paid to the structure of the molecule and its mechanism of action if reported. Subsequent classification of the molecules under discussion has been carried out. Both natural and synthetic and reversible and irreversible EGFR-tyrosine kinase inhibitors have been discussed. Various types of cancers that are caused by overexpression of the EGFR gene, their possible molecular origins, and their natures have also been counted in this article. Because the EGFR signaling pathway controls the proliferation, growth, survival, and differentiation of cells, and the mutated EGFR gene overproduces EGFR protein, which ultimately causes several types of cancer, proper understanding of the molecular dynamics between the protein structure and its inhibitors will lead to more effective and selective EGFR-TKIs, which in turn will be able to save more lives in the battle against cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsLung NeoplasmsHumansProtein Kinase InhibitorsErbB ReceptorsProtein-Tyrosine Kinases

Stichwörter der Autor:innen

anticancer drugscancer therapeuticsepidermal growth factor receptor (EGFR)heterocyclesnatural cancer drugspolycyclic compoundssmall molecule inhibitors

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsErbB ReceptorsProtein-Tyrosine KinasesEGFR protein, human

Autor:innen und Institutionen

  • Department of Chemistry, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA.
  • School of Earth Environment & Marine Sciences (SEEMS), The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA.

ORCID-Profile: Debasish Bandyopadhyay

Zitieren

APA

Zubair, T., & Bandyopadhyay, D. (2023). Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. International Journal of Molecular Sciences, 24(3), 2651. https://doi.org/10.3390/ijms24032651

Vancouver

Zubair T, Bandyopadhyay D. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities. International Journal of Molecular Sciences. 2023;24(3):2651. doi:10.3390/ijms24032651

BibTeX
@article{Zubair2023,
  author = {Zubair, Tanzida and Bandyopadhyay, Debasish},
  title = {Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2651},
  doi = {10.3390/ijms24032651}
}
Kostenlos starten →